# Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

> **NCT02127970** · PHASE3 · COMPLETED · sponsor: **Durata Therapeutics Inc., an affiliate of Allergan plc** · enrollment: 698 (actual)

## Conditions studied

- Abscess
- Wound Infection
- Surgical Site Infection
- Cellulitis

## Interventions

- **DRUG:** Dalbavancin
- **DRUG:** Dalbavancin-matching Placebo

## Key facts

- **NCT ID:** NCT02127970
- **Lead sponsor:** Durata Therapeutics Inc., an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-18
- **Primary completion:** 2015-03-11
- **Final completion:** 2015-03-11
- **Target enrollment:** 698 (ACTUAL)
- **Last updated:** 2018-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02127970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02127970, "Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02127970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*